AUPH - CIK 0001600620
The table below shows Aurinia Pharmaceuticals Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $135.66M | $44.39M | -$33.46M | -$79.53M | -$157.69M | -$69.86M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | -$32.77M | $39.26M | -$6.71M | -$60.63M | -$103.87M | -$158.19M |
| Dividends paid | - | - | - | - | - |
Aurinia Pharmaceuticals Inc. reported operating cash flow of $135.66M for fiscal year 2025. That is up 205.6% from $44.39M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$51.61M (FY 2018) to $135.66M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $98.16M | $40.24M | $0.00 | $0.00 | - | - |
| Financing cash flow | -$106.11M | -$49.09M | -$5.13M | $2.43M | $221.11M | $194.38M |